Imatinib and altered bone and mineral metabolism [9]

New England Journal of Medicine

Volumn 355, Issue 6, 2006, Pages 628-

  Joensuu, Heikki ^a   Reichardt, Peter ^b  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; PHOSPHATE;

CANCER ADJUVANT THERAPY; CLINICAL TRIAL; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; HUMAN; HYPOPHOSPHATEMIA; LETTER; LEUKEMIA; LONGITUDINAL STUDY; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL;

CALCIUM; CHEMOTHERAPY, ADJUVANT; FOLLOW-UP STUDIES; GASTROINTESTINAL STROMAL TUMORS; HUMANS; HYPOPHOSPHATEMIA; PHOSPHATES; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES;

EID: 33746895510     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: None     Document Type: Letter

References (3)

1. Jonsson KB, Zahradnik R, Larsson T, et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 2003;348:1656-63.
2. Carpenter TO. Oncogenic osteomalacia - a complex dance of factors. N Engl J Med 2003;348:1705-8.
3. Ra'anani P, Lahav M, Prokocimer R, Poles L, Theodor E. Life threatening hypophosphatemia in a patient with Philadelphia chromosome-positive chronic myelogenous leukaemia in acute blastic crisis. Postgrad Med J 1992;68:283-6.